Αρχική World News FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications World News FDA Approves Isatuximab-irfc for Subcutaneous Injection for Multiple Myeloma Indications Από Ogkologos - 19 Αυγούστου, 2026 366 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the IRAKLIA, IZALCO and IsaSocut studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Enzalutamide Gets Added Approval for Prostate Cancer That Hasn’t Spread 5 Ιανουαρίου, 2024 Only a Quarter of Phase III Studies Demonstrated Improved QoL in... 18 Ιουλίου, 2022 The long road to targeting the holy grail of the immune... 9 Νοεμβρίου, 2020 ¿Es seguro el CBD para las personas con cáncer? 19 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS Cancer.Net’s 20th Anniversary: Celebrating Our Mission of Providing Trustworthy Cancer Information Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... ¿Puede una biopsia hacer que mi cáncer se disemine? FDA Approves Lazertinib with Amivantamab-vmjw for Locally Advanced or Metastatic NSCLC...